Sorrento Therpt (SRNE)
$8.89 0.41 (4.41%)
19:39 EDT SRNE Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap 1.03B
PE Ratio 44.45
Volume (Avg. Vol.) 13.08M
Day's Range 8.88 - 9.49
52-Week Range 1.45 - 19.39
Dividend & Yield N/A (N/A)
SRNE Stock Predictions, Articles, and Sorrento Therpt News
- From InvestorPlace
- From the Web
There are several established biotech companies for investors to consider but they should avoid buying SRNE stock.
By Ian Cooper
While Sorrento Therapeutics has an impressive pipeline, it needs to bring something to market. The clock is ticking on SRNE stock.
With the novel coronavirus becoming an extended reality for us, no one platform offers a comprehensive solution. And that’s why Sorrento Therapeutics’ all-in pivot bodes well for SRNE stock.
SRNE stock buyers beware. Company management has long targeted unsuspecting biotech investors in never-ending game of fundraising.
While SRNE stock carries a lot of risk, the potential reward from one of its coronavirus plays panning out makes it attractive among biotech stocks.
Sorrento Therapeutics shareholders witnessed SRNE stock gain 70% in the past month. The risk-to-reward proposition has gone from good to bad.
If you love to gamble, SRNE stock is the right one for you. Few other companies, if any, have pivoted as hard as Sorrento did toward Covid-19. Just be aware of the risks.
By Joel Baglole
After running up more than 1,000% this year, Sorrento Therapeutic's stock has pulled back with the broader market in September and is now down 43% from its peak. This retrenchment has spooked many investors. However, patient investors who are willing to stick with Sorrento, or those who buy at the current price, may be rewarded with big future returns.
SRNE stock is up over 200% because the company is taking several bites at the Covid-19 apple. However time is not on the company's side.
Sorrento's multi-pronged approach makes SRNE stock a compelling bet for investors looking to expand their portfolios.
It's a great time to be long SRNE stock as the company's ambitious Covid-19 treatment clinical trials take a giant step forward for Sorrento.
Bears are waging a heavy and crowded bet against SRNE stock, but more good news could send the stock higher.
SRNE stock can benefit from multiple efforts in the fight against the novel coronavirus. Risks are real, but the rewards are as well.
The pandemic has raised awareness about the value of biotech across the world. In turn, these biotech stocks will benefit down the road.
By Thomas Niel
So, what's the call here? If you have a high risk tolerance, and are looking for a short-term pandemic play, SRNE stock today may be worth the risk. Just don't bet the ranch.
Sorrento has some potential positive catalysts, especially its Covid-19 diagnostic test. But SRNE stock is really just for the speculative part of your portfolio.
Lack of a track record, a lagging Covid-19 test project and executive turmoil make SRNE stock a coronavirus play to avoid.
Sorrento Therapeutics just announced plans to launch human trials of its antibody drug. Here's why else SRNE stock is rallying.
From Talk Markets
Navellier RatingsPowered by Portfolio Grader